Generic Risperidone

Buy Generic Risperidone () without prescription in Canada

In our Canadian pharmacy, you can buy Risperidone without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Risperidone is an atypical antipsychotic medication that works by helping to restore the balance of dopamine and serotonin, two key neurotransmitters in the brain. It is primarily used to treat schizophrenia in adults and adolescents aged 13 to 17, as well as acute manic or mixed episodes of bipolar I disorder, either alone or alongside mood stabilizers like lithium or valproate. By blocking specific dopamine and serotonin receptors, it can reduce hallucinations, delusions, and disorganized thinking, while also helping to stabilize mood and prevent relapse.

Usual adult dose: Treatment is started at a low dose of 2 mg per day, which may be increased to 4 mg on the second day. The dose is then adjusted according to response, with most patients benefiting from a range of 4 mg to 8 mg daily, up to a maximum of 16 mg per day. For the elderly, those with liver or kidney problems, or those at risk of low blood pressure, starting doses of 0.5 mg twice daily are recommended and increased more slowly.

Dosage form: Tablets are available in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg strengths. An oral solution (1 mg/mL) and orally disintegrating tablets are also available.

Onset of action: Some improvement in agitation or sleep may be seen within the first 1 to 2 weeks of treatment. However, the full antipsychotic and mood-stabilizing effects typically take several weeks of continuous therapy to develop.

Duration of action: The effects of a single dose last for approximately 24 hours, making once-daily dosing possible for many patients.

Alcohol recommendation: Alcohol consumption should be avoided during treatment with Risperidone. Alcohol can worsen side effects such as dizziness and drowsiness, and it may also interfere with the effectiveness of the medication.

Most common side effects: Drowsiness, restlessness (akathisia), dizziness, headache, constipation, weight gain, and changes in menstrual cycles. Some people may also experience decreased sexual interest or function, and breast swelling or milk production can occur in both males and females.

Would you like to try Risperidone without a prescription?

General Information about Risperidone

• INN (International Nonproprietary Name): Risperidone
• Brand names available in Canada: Risperdal® (Janssen Inc.). Generic versions include Apo‑Risperidone (Apotex Inc.), Teva‑Risperidone (Teva Canada Limited), PMS‑Risperidone (Pharmascience Inc.), Sandoz Risperidone (Sandoz Canada Inc.), JAMP‑Risperidone (JAMP Pharma Corporation), Mar‑Risperidone (Marcan Pharmaceuticals Inc.), Mylan‑Risperidone (Mylan Pharmaceuticals ULC), RAN‑Risperidone (Ranbaxy Pharmaceuticals Canada Inc.), and others.
• ATC code: N05AX08
• Dosage forms and strengths: Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Orally disintegrating tablets (M‑Tab) are available in the same strengths. An oral solution (1 mg/mL) is also available.
• Manufacturers in Canada: Janssen Inc., Apotex Inc., Teva Canada Limited, Pharmascience Inc., Sandoz Canada Inc., JAMP Pharma Corporation, and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Multiple generic formulations are currently marketed and available by prescription.
• OTC / Rx classification: Prescription only (Rx). Risperidone is a Schedule I drug under the Controlled Drugs and Substances Act.

Mechanism of Action and Pharmacology

Risperidone is a benzisoxazole derivative that acts as a potent antagonist at both central serotonin 5‑HT_2A and dopamine D₂ receptors. Its therapeutic effects in schizophrenia are thought to be mediated through this combined antagonism, with the blockade of D₂ receptors addressing positive symptoms (hallucinations, delusions) and the blockade of 5‑HT_2A receptors contributing to improvements in negative symptoms (social withdrawal, blunted affect) and reducing the risk of movement‑related side effects. Risperidone also blocks alpha‑1 adrenergic and histamine H₁ receptors, and has moderate affinity for alpha‑2 adrenergic receptors. It has weak affinity for 5‑HT_1A receptors and little or no affinity for muscarinic M₁ receptors, which accounts for a lower incidence of anticholinergic side effects compared with some older antipsychotics.

Following oral administration, risperidone is well absorbed and undergoes extensive first‑pass hepatic metabolism, primarily by cytochrome P450 2D6, to its major active metabolite, 9‑hydroxyrisperidone (paliperidone), which is pharmacologically equipotent to the parent drug. The combined active moiety (risperidone plus 9‑hydroxyrisperidone) has an elimination half‑life of approximately 20 to 24 hours, supporting once‑daily dosing. Steady‑state concentrations are reached within 1 to 2 days of regular dosing. The drug is eliminated primarily via the kidneys, and dose adjustment is required in patients with severe renal impairment.

Indications

• Schizophrenia: For the acute and maintenance treatment of schizophrenia in adults and adolescents aged 13 to 17 years.
• Bipolar I Disorder: As monotherapy or as adjunctive therapy with lithium or valproate for the treatment of acute manic or mixed episodes associated with bipolar I disorder in adults and children aged 10 years and older.
• Irritability Associated with Autistic Disorder: For the treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years.
• Off‑label Uses: Risperidone is also prescribed off‑label for a variety of other conditions, including behavioural and psychological symptoms of dementia (though use in elderly patients with dementia‑related psychosis is associated with an increased risk of death), tic disorders, aggression, and severe behavioural disturbances.

Important Warnings and Precautions

At‑risk groups

• Elderly (Dementia‑Related Psychosis): Elderly patients with dementia‑related psychosis treated with antipsychotic drugs are at an increased risk of death. Most deaths appear to be cardiovascular or infectious in nature. Risperidone is not approved for the treatment of dementia‑related psychosis and should be used with extreme caution in this population. Health Canada has limited its indication to severe dementia of the Alzheimer type only.
• Pregnancy: There are no adequate and well‑controlled studies of risperidone in pregnant women. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the foetus. Neonates exposed to antipsychotics in the third trimester are at risk for extrapyramidal and/or withdrawal symptoms after delivery.
• Breastfeeding: Risperidone and its active metabolite are excreted in human breast milk. A decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics: Safety and efficacy have been established for specific indications in children and adolescents; however, monitoring is critical. In short‑term placebo‑controlled trials, children and adolescents experienced a higher incidence of somnolence, fatigue, and headache.
• Elderly: Elderly patients may be more sensitive to the sedative and hypotensive effects of risperidone, and they are at higher risk of orthostatic hypotension, confusion, and falls. Lower starting doses are recommended, with careful upward titration.
• Renal Impairment: The clearance of the active moiety is reduced in patients with moderate to severe renal impairment. A lower starting dose and slower upward titration are recommended.
• Hepatic Impairment: In patients with severe hepatic impairment, use with caution, and a lower starting dose is recommended. Liver function tests should be monitored.
• Cardiovascular Disease: Risperidone can cause orthostatic hypotension, particularly during the initial dose‑titration period. Use with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions that predispose to hypotension.
• Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal condition characterized by hyperthermia, severe muscle rigidity, altered mental status, and autonomic instability has been reported with antipsychotic drugs, including risperidone. Immediate discontinuation of the drug and intensive supportive care are required.
• QT Prolongation: Risperidone may prolong the QT interval on an ECG. Use with caution in patients with risk factors for QT prolongation, including electrolyte disturbances, concomitant use of QT‑prolonging drugs, and congenital long QT syndrome.
• Seizure Disorders: Antipsychotics may lower the seizure threshold. Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.
• Diabetes Mellitus: Risperidone is associated with metabolic changes, including hyperglycaemia and new‑onset type 2 diabetes mellitus. Baseline and periodic monitoring of fasting blood glucose is recommended, especially in patients with risk factors.
• Hyperprolactinaemia: Risperidone elevates prolactin levels, which may lead to galactorrhoea, amenorrhoea, gynaecomastia, and sexual dysfunction. The effect is dose‑dependent.
• Allergy: Do not take risperidone if you have a known hypersensitivity to risperidone or paliperidone, or any excipient in the formulation.

Driving and alcohol

Risperidone can cause significant sedation, drowsiness, and impaired cognitive and motor skills. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they have determined how the medication affects them. Alcohol should be avoided during treatment, as it can potentiate the CNS‑depressant effects of risperidone and increase the risk of dizziness, poor concentration, drowsiness, and other adverse effects.

Dosage Instructions

• Schizophrenia (Adults): The recommended initial dose is 2 mg per day, taken as a single dose or in two divided doses. The dose may be increased to 4 mg on the second day. Thereafter, the dose may be adjusted at intervals of 24 hours or greater, in increments of 1 mg per day, as tolerated. The effective dose range is 4 mg to 8 mg per day, with a maximum dose of 16 mg daily. In long‑term studies, doses above 10 mg daily have not demonstrated superior efficacy and are associated with a higher incidence of extrapyramidal symptoms.
• Schizophrenia (Adolescents 13–17 Years): The initial dose is 0.5 mg once daily, which may be increased to 1 mg on the second day. Thereafter, the dose may be adjusted in increments of 0.5 mg to 1 mg per day at intervals of 24 hours or greater. The effective dose range is 1 mg to 6 mg per day. Doses above 6 mg daily have not been studied in this population.
• Bipolar Mania (Adults): The initial dose is 2 mg to 3 mg per day, given as a single dose or in two divided doses. The dose may be adjusted by 1 mg per day at intervals of 24 hours or greater. The effective dose range is 1 mg to 6 mg per day.
• Irritability Associated with Autistic Disorder (Children and Adolescents): Dosing is based on weight. For patients weighing less than 20 kg, the initial dose is 0.25 mg per day, with a target dose of 0.5 mg per day. For those 20 kg or more, the initial dose is 0.5 mg per day, with a target dose of 1 mg per day. The dose may be maintained at the target dose for at least 14 days, and then increased in 0.25 mg or 0.5 mg increments at intervals of 2 weeks or more.
• Elderly, Renally Impaired, or Hepatically Impaired Patients: Starting doses of 0.5 mg twice daily are recommended. The dose may be increased in increments of 0.5 mg twice daily to 1 mg to 2 mg twice daily. Slower titration and lower maintenance doses are recommended.
• Administration: Risperidone may be taken with or without food. The oral solution can be mixed with water, orange juice, coffee, or low‑fat milk; it should not be mixed with tea or cola. The orally disintegrating tablets should be placed on the tongue and allowed to dissolve; they should not be chewed or swallowed whole.
• Missed Dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not double the dose.
• Discontinuation: Gradual tapering of the dose is recommended when discontinuing risperidone, as abrupt discontinuation may cause withdrawal symptoms such as nausea, vomiting, sweating, and insomnia.

Side Effects and Contraindications

• Common side effects (incidence ≥ 5%): Somnolence, extrapyramidal symptoms (dystonia, akathisia, parkinsonism, tremor), headache, dizziness, nausea, constipation, dyspepsia, abdominal pain, fatigue, and weight gain. Nasopharyngitis and rhinitis are also common.
• Less common but serious side effects: Orthostatic hypotension, tachycardia, QT prolongation, hyperprolactinaemia, hyperglycaemia and new‑onset diabetes mellitus, neuroleptic malignant syndrome (NMS), tardive dyskinesia, seizures, cerebrovascular events (including stroke, particularly in elderly patients with dementia), and agranulocytosis. Pituitary adenomas and priapism have also been reported in post‑marketing surveillance.
• Extrapyramidal Symptoms (EPS): The risk of EPS with risperidone is dose‑related. At the recommended clinical dose range of 4 mg to 8 mg per day, the incidence of EPS is comparable to placebo. Above 10 mg per day, the incidence of EPS increases significantly and may be similar to that of typical antipsychotics.
• Post‑marketing Reports: Alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, catatonia, diabetic ketoacidosis, hypoglycaemia, hypothermia, ileus, inappropriate antidiuretic hormone secretion, intestinal obstruction, jaundice, mania, pancreatitis, precocious puberty, pulmonary embolism, sleep apnea syndrome, somnambulism, Stevens‑Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), sudden death, thrombocytopenia, thrombotic thrombocytopenic purpura, urinary retention, and water intoxication.
• Contraindications: Known hypersensitivity to risperidone or paliperidone, or to any excipient in the formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported.

Drug Interactions

• Major Interactions (Avoid Concomitant Use): Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, and antibiotics) increase the risk of cardiac arrhythmias when used with risperidone. Concomitant use of risperidone with other centrally acting drugs and alcohol should be undertaken with caution.
• CNS Depressants: Alcohol, benzodiazepines, opioids, and other CNS depressants may increase the sedative effects of risperidone and impair cognitive and motor performance.
• Levodopa and Dopamine Agonists: Risperidone may antagonize the therapeutic effects of levodopa and other dopamine agonists, which are used to treat Parkinson's disease. This combination should generally be avoided or used with caution.
• Antihypertensives: Risperidone may enhance the hypotensive effects of antihypertensive medications. Blood pressure should be monitored when these drugs are co‑administered.
• Methylphenidate: Concomitant use with methylphenidate, when there is a change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). Patients should be closely monitored.
• Drugs Affecting Hepatic Metabolism: CYP2D6 enzyme inhibitors (e.g., fluoxetine, paroxetine) can increase risperidone plasma levels, requiring a dose reduction. CYP3A4 enzyme inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin) can decrease risperidone plasma levels, potentially requiring a dose increase.
• Valproate and Lithium: No clinically significant pharmacokinetic interactions have been observed when risperidone is co‑administered with valproate or lithium. However, lithium can prolong the QT interval, and caution is advised when these drugs are used together.

Practical Advice

• Administration: Take risperidone exactly as prescribed by your doctor. It can be taken with or without food, once or twice daily. If you are taking the oral solution, measure the dose carefully using the calibrated pipette provided. Do not mix the solution with cola or tea.
• Monitoring: Regular follow‑up with your doctor is essential. This will include monitoring of your weight, blood pressure, fasting blood glucose, lipid profile, and liver function tests. An electrocardiogram (ECG) may be performed before and during treatment, especially if you have risk factors for heart rhythm problems. Your doctor will also monitor for signs of extrapyramidal symptoms (tremor, rigidity, restlessness, involuntary movements) and tardive dyskinesia (persistent, abnormal movements, especially of the face and tongue).
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from light and moisture. Keep the oral solution in its original bottle and use within the timeframe recommended by the pharmacist. Keep out of the reach and sight of children.
• Lifestyle: A healthy diet and regular exercise are important to help manage the weight gain that often accompanies risperidone therapy. Rise slowly from a sitting or lying position to minimize the risk of dizziness or fainting. Avoid overheating and dehydration, as risperidone can interfere with the body’s ability to regulate temperature.
• Missed Dose: If you miss a dose, take it as soon as you remember on the same day. If it is close to the time of your next dose, skip the missed dose and return to your regular schedule. Never take a double dose to make up for a missed one.
• When to seek medical review: Contact your doctor immediately if you develop signs of neuroleptic malignant syndrome (high fever, severe muscle stiffness, confusion, rapid or irregular heartbeat), allergic reaction (rash, swelling of the face or throat, difficulty breathing), or tardive dyskinesia (uncontrollable movements of the face, tongue, or limbs).
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other Atypical Antipsychotics: Olanzapine (Zyprexa), quetiapine (Seroquel), and aripiprazole (Abilify) are other second‑generation antipsychotics used for similar conditions. The choice depends on individual patient factors, including side‑effect profiles. For example, olanzapine is often associated with more weight gain and metabolic side effects, while aripiprazole has a different receptor profile that may be less likely to cause prolactin elevation.
• Typical Antipsychotics: Haloperidol (Haldol) is a first‑generation antipsychotic that is effective for the positive symptoms of schizophrenia but carries a much higher risk of extrapyramidal symptoms and tardive dyskinesia.
• Mood Stabilizers: For bipolar disorder, lithium or valproate are first‑line treatments that may be used as alternatives to or in combination with an antipsychotic.
• Paliperidone (Invega): Paliperidone is the active metabolite of risperidone and is available in extended‑release oral and long‑acting injectable formulations. It offers a similar therapeutic profile with the convenience of once‑daily dosing without the need for initial titration.

Clinical Efficacy

The efficacy of risperidone in the treatment of schizophrenia has been demonstrated in multiple randomized, double‑blind, placebo‑controlled clinical trials involving over a thousand patients. In a large 8‑week dose‑comparison trial, doses of risperidone of 4 mg, 8 mg, 12 mg, and 16 mg per day were all superior to a 1 mg dose on measures of total psychopathology and positive psychotic symptoms, with the most consistent responses seen for the 4 mg dose group. The 6 mg dose group also showed consistently positive responses in earlier fixed‑dose studies, and there was no suggestion of increased benefit at doses above 10 mg per day.

A recent meta‑analysis comparing antipsychotics for acute schizophrenia symptoms found that olanzapine and risperidone produced the greatest overall reduction in Positive and Negative Syndrome Scale (PANSS) total scores compared with other commonly prescribed agents, with response rates of approximately 68%. Long‑term studies have demonstrated that patients treated with risperidone experience a significantly longer time to relapse compared with those receiving older typical antipsychotics, supporting its role as a first‑line maintenance therapy. In the treatment of bipolar mania, risperidone as monotherapy or adjunctive therapy has been shown to reduce manic symptoms rapidly and effectively. For the irritability associated with autistic disorder, risperidone has been shown to significantly reduce aggression, self‑injurious behaviour, and severe tantrums in children and adolescents. The tolerability profile of risperidone is generally favorable at the recommended dose range, with a low incidence of extrapyramidal symptoms and a manageable metabolic impact, although weight gain and hyperprolactinaemia remain notable concerns.

Important:

Risperidone is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It can cause serious, life‑threatening adverse effects, including neuroleptic malignant syndrome, severe cardiac arrhythmias, and cerebrovascular events, particularly in elderly patients with dementia. Do not discontinue this medication abruptly, as this may lead to a rapid return of psychotic symptoms. If you experience symptoms such as high fever, severe muscle stiffness, confusion, rapid or irregular heartbeat, uncontrollable movements of the face or tongue, or signs of a severe allergic reaction (such as rash, swelling of the face, tongue, or throat, and difficulty breathing), stop taking the medication and seek emergency medical attention immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Risperidone - Shipping across Canada